Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
CTNM Stock Price Chart
Explore Contineum Therapeutics, Inc. Class A Common Stock interactive price chart. Choose custom timeframes to analyze CTNM price movements and trends.
CTNM Company Profile
Discover essential business fundamentals and corporate details for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
41.00
Website
https://www.contineum-tx.comCEO
Carmine N. Stengone MBA, MS
Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
CTNM Financial Timeline
Browse a chronological timeline of Contineum Therapeutics, Inc. Class A Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.54, while revenue estimate is $6.00M.
Earnings released on 5 Aug 2025
EPS came in at -$0.62 falling short of the estimated -$0.56 by -10.71%.
Earnings released on 14 May 2025
EPS came in at -$0.62 falling short of the estimated -$0.56 by -10.71%.
Earnings released on 6 Mar 2025
EPS came in at -$0.56 falling short of the estimated -$0.44 by -27.27%.
Earnings released on 6 Nov 2024
EPS came in at -$0.40 surpassing the estimated -$0.41 by +2.44%.
Earnings released on 13 Aug 2024
EPS came in at -$0.39 falling short of the estimated -$0.37 by -5.41%.
Earnings released on 16 May 2024
EPS came in at -$3.55 falling short of the estimated -$0.46 by -671.74%.
Earnings released on 31 Dec 2023
EPS came in at -$0.31 .
Earnings released on 30 Sept 2023
EPS came in at -$0.25 .
Earnings released on 30 Jun 2023
EPS came in at $1.62 , while revenue for the quarter reached $50.00M .
Earnings released on 31 Mar 2023
EPS came in at -$0.19 .
Earnings released on 31 Dec 2022
EPS came in at -$0.30 .
CTNM Stock Performance
Access detailed CTNM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.